HUE059559T2 - 5HT agonisták az epilepsziás rendellenességek kezelésére - Google Patents

5HT agonisták az epilepsziás rendellenességek kezelésére

Info

Publication number
HUE059559T2
HUE059559T2 HUE16756282A HUE16756282A HUE059559T2 HU E059559 T2 HUE059559 T2 HU E059559T2 HU E16756282 A HUE16756282 A HU E16756282A HU E16756282 A HUE16756282 A HU E16756282A HU E059559 T2 HUE059559 T2 HU E059559T2
Authority
HU
Hungary
Prior art keywords
agonists
treatment
epileptic disorders
epileptic
disorders
Prior art date
Application number
HUE16756282A
Other languages
English (en)
Hungarian (hu)
Inventor
Scott Baraban
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HUE059559T2 publication Critical patent/HUE059559T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE16756282A 2015-02-25 2016-02-24 5HT agonisták az epilepsziás rendellenességek kezelésére HUE059559T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25

Publications (1)

Publication Number Publication Date
HUE059559T2 true HUE059559T2 (hu) 2022-12-28

Family

ID=56789223

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16756282A HUE059559T2 (hu) 2015-02-25 2016-02-24 5HT agonisták az epilepsziás rendellenességek kezelésére

Country Status (21)

Country Link
US (5) US10874643B2 (https=)
EP (4) EP4043016B1 (https=)
JP (5) JP6884703B2 (https=)
KR (3) KR20220048045A (https=)
CN (2) CN113546174A (https=)
AU (3) AU2016222804C1 (https=)
BR (1) BR112017018297B1 (https=)
CA (2) CA2977135C (https=)
CY (1) CY1125360T1 (https=)
DK (1) DK3261640T3 (https=)
EA (2) EA201992474A3 (https=)
ES (2) ES2920886T3 (https=)
HR (1) HRP20220822T1 (https=)
HU (1) HUE059559T2 (https=)
LT (1) LT3261640T (https=)
PL (1) PL3261640T3 (https=)
PT (1) PT3261640T (https=)
RS (1) RS63426B1 (https=)
SI (1) SI3261640T1 (https=)
SM (1) SMT202200276T1 (https=)
WO (1) WO2016138138A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US12268683B2 (en) 2018-07-18 2025-04-08 The Regents Of The University Of California Compounds and methods for synergistic activation of M channels
WO2020023923A1 (en) * 2018-07-27 2020-01-30 Xenon Pharmaceuticals Inc. Method for treating epilepsy
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
EP3976187A4 (en) * 2019-05-29 2023-08-02 The Regents of the University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPILEPSY
EP3791873A1 (en) 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
KR20220087507A (ko) * 2019-10-23 2022-06-24 뉴로사이클 테라퓨틱스, 인크. Gabaa 수용체 조절제를 사용한 간질 병태의 치료
FI4048249T3 (fi) * 2019-10-23 2025-12-05 Maplight Therapeutics Inc Menetelmiä autismikirjon häiriön oireiden hoitamiseksi
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
JP7780431B2 (ja) * 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
BR112023019407A2 (pt) * 2021-03-25 2023-11-28 Maplight Therapeutics Inc Composições farmacêuticas compreendendo zolmitriptano
EP4346804A4 (en) * 2021-06-01 2025-05-07 Arena Pharmaceuticals, Inc. TREATMENT PROCEDURES
CN117580579A (zh) * 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物
CN118043034A (zh) * 2021-07-30 2024-05-14 艾匹真尼克斯治疗公司 克立咪唑制剂
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023212244A1 (en) * 2022-04-27 2023-11-02 Tessellate Therapeutics, Inc. Methods of treating 5ht2a receptor-mediated conditions
CA3247344A1 (en) 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
WO2024118280A1 (en) * 2022-11-30 2024-06-06 Mind Medicine, Inc. 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action
CN119564685B (zh) * 2024-12-16 2026-02-06 中国人民解放军军事科学院军事医学研究院 Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20050215589A1 (en) 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US8642351B2 (en) 2006-09-20 2014-02-04 Waters Technologies Corporation Apparatus and methods of fluid chromatography
US8402815B2 (en) 2007-04-06 2013-03-26 Koninklijke Philips Electronics N.V. Air pollution sensor system
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
CA2687715A1 (en) 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
EP2203168B1 (en) 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
BRPI0908098A2 (pt) 2008-02-19 2015-08-18 Adolor Corp Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2
CN102066319A (zh) 2008-04-16 2011-05-18 艾尼纳制药公司 用于合成(r)-1-{2-[4’-(3-甲氧基丙-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的方法
DK2307035T3 (da) 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
WO2010039195A2 (en) 2008-09-23 2010-04-08 The Board Of Trustees Of The Leland Stanford Junior University Screening for inhibitors of hcv amphipathic helix (ah) function
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
EP2408448A4 (en) 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
US8772479B2 (en) 2009-05-13 2014-07-08 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
EP2491033A4 (en) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3035926T3 (da) * 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015096119A1 (zh) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
AU2021204261A1 (en) 2021-07-29
CA3204599A1 (en) 2016-09-01
EP3261640B1 (en) 2022-04-06
EP3261640A1 (en) 2018-01-03
ES2920886T3 (es) 2022-08-11
RS63426B1 (sr) 2022-08-31
US20210154171A1 (en) 2021-05-27
US11648237B2 (en) 2023-05-16
LT3261640T (lt) 2022-07-11
JP2020143087A (ja) 2020-09-10
SI3261640T1 (sl) 2022-10-28
US20260083706A1 (en) 2026-03-26
EA201992474A2 (ru) 2020-02-28
KR20220048045A (ko) 2022-04-19
HRP20220822T1 (hr) 2022-10-28
BR112017018297A2 (pt) 2018-04-17
JP2022116307A (ja) 2022-08-09
CA2977135C (en) 2023-08-22
AU2016222804C1 (en) 2021-10-14
AU2022203274A1 (en) 2022-06-16
EP3632434A1 (en) 2020-04-08
JP6884703B2 (ja) 2021-06-09
JP2021185148A (ja) 2021-12-09
WO2016138138A1 (en) 2016-09-01
CA2977135A1 (en) 2016-09-01
EA201791882A1 (ru) 2018-02-28
ES3060954T3 (en) 2026-03-30
EP4696377A2 (en) 2026-02-18
CN107530326B (zh) 2021-09-21
AU2022203274B2 (en) 2024-08-15
JP2018506555A (ja) 2018-03-08
PT3261640T (pt) 2022-07-06
KR102385665B1 (ko) 2022-04-14
CY1125360T1 (el) 2025-05-09
EP4043016A1 (en) 2022-08-17
DK3261640T3 (da) 2022-07-11
AU2016222804A1 (en) 2017-08-31
JP7846506B2 (ja) 2026-04-15
EP3261640A4 (en) 2018-12-19
CN107530326A (zh) 2018-01-02
PL3261640T3 (pl) 2022-10-31
CN113546174A (zh) 2021-10-26
US12447144B2 (en) 2025-10-21
BR112017018297B1 (pt) 2023-12-05
AU2021204261B2 (en) 2023-08-10
EP4696377A3 (en) 2026-04-29
SMT202200276T1 (it) 2022-09-14
JP2024009839A (ja) 2024-01-23
US20230346750A1 (en) 2023-11-02
EA201992474A3 (ru) 2020-05-31
US20180028499A1 (en) 2018-02-01
KR20230152844A (ko) 2023-11-03
KR20170118870A (ko) 2017-10-25
EP4043016B1 (en) 2025-10-29
US10874643B2 (en) 2020-12-29
AU2016222804B2 (en) 2021-07-15
US20200147048A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
HUE059559T2 (hu) 5HT agonisták az epilepsziás rendellenességek kezelésére
IL285151A (en) Methods of treating fgf21-associated disorders
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
IL256166B (en) Compounds for use in treating neuromuscular disorders
PT3119397T (pt) Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
IL247452A0 (en) Compounds for treatment of complement mediated disorders
PL3265053T3 (pl) Sposoby leczenia skóry
IL253945A0 (en) kdm1a inhibitors to treat the disease
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
IL258412A (en) Melanocortin-4 receptor (mc4r) agonists for use in treating melanocortin-4 receptor pathway-associated disorders
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
HUE064604T2 (hu) Menotropin meddõség kezelésére
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
IL263080B (en) Treatment of neurological disorders
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
IL262801A (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
PL3423440T3 (pl) Pochodna 5-metylo-6-fenylo-4,5-dihydro-2h-pirydazyn-3-onu do leczenia nowotworów mózgu
DK3395350T3 (da) Lægemiddel til behandling af hjerneinfarkt